ClinicalTrials.gg
RecruitingNCT06874803WARMEDUpdated Jul 20, 2025

Acupuncture and Moxibustion for Motor Symptoms in Early Parkinson's Disease

An interventional study of Acupuncture and Moxibustion (AM) and Sham Acupuncture and Moxibustion (Sham-AM) in Parkinson's Disease (PD), sponsored by Jiani Wu. Recruiting at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-20.

Sponsored by Jiani Wu · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Aug 2024, registered Feb 2025).
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Planned enrollment
74th of 211
60 · median 47
Started
2024
with 30 others
No phase
115 of 279
57 open now
Primary completion
2025-08
later than 29 of 134 live
Registered
201st of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 74th largest by planned enrollment of the 211 interventional ones that give a count, is one of 31 that started in 2024, is one of 115 with no phase, reaches primary completion later than 29 of the 134 other live ones, and was the 201st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

This study evaluates the clinical effect and safety of acupuncture combined with moxibustion in improving motor symptoms of early-stage Parkinson's Disease (PD) patients, by assessing the changes in UPDRS scores. It also explores objective factors affecting the acupuncture effect and investigates the functional MRI mechanisms of acupuncture in PD treatment.

03

Conditions studied

  • Parkinson's Disease (PD)

Keywords

  • Acupuncture
  • Moxibustion
  • Parkinson's Disease
  • Motor Symptoms
  • Rigidity
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria:

1. Diagnosed with Parkinson's disease (PD) according to the 2016 Chinese 2. Diagnostic Criteria for Parkinson's Disease.

3. Hoehn-Yahr stage \<3 (mild to moderate PD). 4. Age between 30 and 80 years (inclusive). 5. Signed indicating voluntary participation.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded:

  1. Diagnosed with Parkinson-plus syndromes or other secondary parkinsonism.
  2. Prior history of deep brain stimulation (DBS) surgery.
  3. Severe cerebrovascular disease, brain trauma, or history of craniotomy.
  4. Severe dementia or psychiatric disorders that prevent cooperation with study procedures.
  5. Severe coagulation disorders.
  6. Presence of severe systemic organ dysfunction (cardiac, pulmonary, hepatic, renal, endocrine, or metabolic disorders).
  7. Pregnant or breastfeeding women.
  8. History of allergic reaction to acupuncture or moxibustion.
  9. Prior treatment with acupuncture or moxibustion within the past three months.
  10. Participation in another clinical trial within the past three months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Acupuncture and Moxibustion Group (AM)

    Participants in this group will receive acupuncture and moxibustion therapy alongside standard Parkinson's disease (PD) medication. Acupuncture at Shuifen (CV9), bilateral Yinlingquan (SP9), bilateral Zhongliao (BL33), and bilateral Weiyang (BL39), combined with moxibustion at Shuifen (CV9) and Zhongliao (BL33). Each participant will undergo treatment three times per week for eight weeks (24 total sessions). Standard PD medication will remain unchanged throughout the study.

    Procedure: Acupuncture and Moxibustion (AM)

  • Sham comparator
    Sham Acupuncture and Moxibustion Group (Sham-AM)

    Participants in this group will receive sham acupuncture and sham moxibustion alongside standard PD medication. Acupuncture at non-acuipoints of bilateral Hegu (LI4) and bilateral Zusanli (ST36), with fake moxibustion at Shuifen (CV9) and bilateral Zhongliao (BL33). Treatments will be conducted three times per week for eight weeks (24 total sessions). Standard PD medication will remain unchanged.

    Procedure: Sham Acupuncture and Moxibustion (Sham-AM)

Interventions

  • ProcedureAcupuncture and Moxibustion (AM)

    Acupuncture and moxibustion group (AM): Acupuncture at Shuifen (CV9), bilateral Yinlingquan (SP9), bilateral Zhongliao (BL33), and bilateral Weiyang (BL39), combined with moxibustion at Shuifen (CV9) and Zhongliao (BL33).

  • ProcedureSham Acupuncture and Moxibustion (Sham-AM)

    Sham acupuncture and moxibustion group (sham-AM): Acupuncture at non-acuipoints of bilateral Hegu (LI4) and bilateral Zusanli (ST36), with fake moxibustion at Shuifen (CV9) and bilateral Zhongliao (BL33).

06

What researchers measure

Primary outcomes

  1. The score change from baseline in the MDS-UPDRS part III after 8-week treatment

    The MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale) Part III assesses motor function in Parkinson's disease patients. It evaluates a range of motor symptoms, including tremor, rigidity, bradykinesia, postural instability, and gait. The scale is widely used to track disease progression and response to treatment. It consists of 26 items, scored based on the severity of each symptom.

    Time frame: evaluation time points: baseline, week 8.

Secondary outcomes

  1. The score change from baseline in the MDS-UPDRS part III after 8-week follow-up

    The MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale) Part III assesses motor function in Parkinson's disease patients. It evaluates a range of motor symptoms, including tremor, rigidity, bradykinesia, postural instability, and gait. The scale is widely used to track disease progression and response to treatment. It consists of 26 items, scored based on the severity of each symptom.

    Time frame: evaluation time points: baseline, week 16.

  2. Changes in VAS scores of rigidity and bradykinesia after 8-week treatment and 8-week follow-up

    The VAS range from 0-10, with higher score indicating more severe symptoms

    Time frame: evaluation time points: baseline, week 8, week 16.

  3. The score change from baseline in the MDS-UPDRS part II after 8-week treatment and 8-week follow-up

    The MDS-UPDRS Part II evaluates the activities of daily living (ADL) in Parkinson's disease patients. It assesses how motor and non-motor symptoms impact daily functioning, including tasks such as dressing, eating, and walking. This section helps in understanding the patient's ability to perform everyday activities. It consists of 13 items, each scored based on the level of difficulty experienced.

    Time frame: evaluation time points: baseline, week 8, week 16.

  4. The change from baseline in the MDS-UPDRS total score after 8-week treatment and 8-week follow-up

    The MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale) is a comprehensive tool used to assess the severity of Parkinson's disease symptoms. It is divided into four parts: motor examination (Part III), activities of daily living (Part II), non-motor experiences of daily living (Part I), and motor complications (Part IV). This scale helps in tracking disease progression, evaluating treatment efficacy, and improving clinical decision-making.

    Time frame: evaluation time points: baseline, week 8, week 16.

  5. The proportion of participants with ≥30% decrease of MDS-UPDRS Part III after 8-week treatment and 8-week follow-up

    The MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale) Part III assesses motor function in Parkinson's disease patients. It evaluates a range of motor symptoms, including tremor, rigidity, bradykinesia, postural instability, and gait. The scale is widely used to track disease progression and response to treatment. It consists of 26 items, scored based on the severity of each symptom.

    Time frame: evaluation time points: baseline, week 8, week 16.

  6. The change from baseline in PDQ-39 after 8-week treatment and 8-week follow-up

    The PDQ-39 (Parkinson's Disease Questionnaire-39) is a patient-reported outcome measure used to assess the health-related quality of life in Parkinson's disease patients. It includes 39 items covering eight domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and sleep. Each item is scored based on the degree of difficulty or discomfort, and the results are summarized to provide an overall score. Higher scores indicate greater impairment in quality of life.

    Time frame: evaluation time points: baseline, week 8, week 16.

  7. The change from baseline in PDSS after 8-week treatment and 8-week follow-up

    The Parkinson's Disease Sleep Scale (PDSS) is a tool used to assess sleep disturbances in Parkinson's disease patients. It consists of 15 items, covering sleep quality, nighttime symptoms, and daytime sleepiness. Each item is rated on a scale from 0 to 4, with higher scores indicating more severe sleep problems. The total score helps to evaluate the overall impact of sleep disturbances on the patient's quality of life.

    Time frame: evaluation time points: baseline, week 8, week 16.

  8. The change from baseline in SDS after 8-week treatment and 8-week follow-up

    The Self-Rating Depression Scale (SDS) is a tool used to assess the severity of depressive symptoms. It consists of 20 items, each addressing mood, behavior, and physical symptoms related to depression. Each item is scored on a 4-point scale, ranging from "none" to "severe." Higher total scores indicate more severe depressive symptoms, helping to assess the patient's mental health status.

    Time frame: evaluation time points: baseline, week 8, week 16.

  9. The change from baseline in SAS after 8-week treatment and 8-week follow-up

    The Self-Rating Anxiety Scale (SAS) is a tool used to assess the severity of anxiety symptoms. It consists of 20 items, which evaluate physical and psychological symptoms of anxiety. Each item is scored on a 4-point scale, from "none" to "severe." Higher total scores indicate greater levels of anxiety, helping to gauge the patient's emotional and mental state.

    Time frame: evaluation time points: baseline, week 8, week 16.

  10. The change from baseline in functional MRI signals after 8-week treatment.

    The hospital's radiology department uses functional magnetic resonance imaging (fMRI) to measure and map brain activity by detecting changes in blood oxygen level-dependent (BOLD) signals in different brain regions.

    Time frame: evaluation time points: baseline, week 8.

  11. Subgroup analysis of gender in the score change from baseline in the MDS-UPDRS part III after 8-week treatment

    Stratifying by gender into male and female subgroups, we assessed the difference in MDS-UPDRS Part III scores within each subgroup to compare the efficacy between men and women. The MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale) Part III assesses motor function in Parkinson's disease patients. It evaluates a range of motor symptoms, including tremor, rigidity, bradykinesia, postural instability, and gait. The scale is widely used to track disease progression and response to treatment. It consists of 26 items, scored based on the severity of each symptom.

    Time frame: evaluation time points: baseline, week 8.

  12. Subgroup analysis of age in the score change from baseline in the MDS-UPDRS part III after 8-week treatment

    Age stratification was performed by dividing participants into two subgroups: those younger than 60 years and those aged 60 and above. The difference in MDS-UPDRS Part III scores was assessed within each subgroup to compare the treatment efficacy between the two age subgroups. The MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale) Part III assesses motor function in Parkinson's disease patients. It evaluates a range of motor symptoms, including tremor, rigidity, bradykinesia, postural instability, and gait. The scale is widely used to track disease progression and response to treatment. It consists of 26 items, scored based on the severity of each symptom.

    Time frame: evaluation time points: baseline, week 8.

  13. Subgroup analysis of disease severity in the score change from baseline in the MDS-UPDRS part III after 8-week treatment

    Patients were stratified based on disease severity using the Hoehn and Yahr staging system into four subgroups: stage 1, 1.5, 2, and 2.5. The efficacy differences across disease stages were assessed by evaluating the change in MDS-UPDRS Part III scores within each subgroup. The difference in MDS-UPDRS Part III scores was assessed within each subgroup to compare the treatment efficacy between the two age subgroups. The MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale) Part III assesses motor function in Parkinson's disease patients. It evaluates a range of motor symptoms, including tremor, rigidity, bradykinesia, postural instability, and gait. The scale is widely used to track disease progression and response to treatment. It consists of 26 items, scored based on the severity of each symptom.

    Time frame: evaluation time points: baseline, week 8.

Other outcomes

  1. The proportion of patients in intervention-related adverse events after 8-week treatment

    Acupuncture-related adverse reactions include: severe acupuncture site pain (VAS \> 7), acupuncture site pain lasting more than 30 minutes, and local subcutaneous hematoma in the stimulated area. Moxibustion-related adverse reactions include: local redness and swelling, burns, and blistering. For medicines, please refer to the drug's instructions.

    Time frame: evaluation time points: from baseline to the end of week 8.

  2. The proportion of patients with adherence ≥80%

    Patient adherence is assessed using the treatment frequency count method to estimate the subjects' adherence. A good adherence criterion is defined as having received 80% or more of the scheduled treatments. Adherence is calculated by dividing the number of treatments received by the number of treatments expected, multiplied by 100%.

    Time frame: evaluation time points: from baseline to the end of week 8.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) will be shared, including all IPD that underlie the results reported in future publications. The data will include demographic information, clinical assessments, MDS-UPDRS scores, VAS scores, PDQ-39 scores, PDSS scores, SAS/SDS scores, and fMRI imaging data.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: IPD will be available starting 6 months after publication of the primary results and will remain accessible for at least 5 years.

Access criteria: by email

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Aug 2025, 12 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 12 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Mar 13, 2025
StartActual
Aug 1, 2024
Primary completionEst.
Aug 31, 2025
CompletionEst.
Aug 31, 2026
Last update
Jul 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06874803
Lead sponsor
Jiani Wu
Responsible party
Jiani Wu (Associate Chief Physician, Guang'anmen Hospital of China Academy of Chinese Medical Sciences) — Sponsor-investigator
First posted
Mar 13, 2025
Start date
Aug 1, 2024
Primary completion
Aug 31, 2025 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Jul 20, 2025

Study contacts

Yu Liu, MD
Contact
yliu133@mgh.harvard.edu
8572650199

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion